Owens & Minor/$OMI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Owens & Minor

Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.

Ticker

$OMI
Sector

Primary listing

NYSE

Employees

23,200

Owens & Minor Metrics

BasicAdvanced
$423M
-
-$15.63
1.03
-

What the Analysts think about Owens & Minor

Analyst ratings (Buy, Hold, Sell) for Owens & Minor stock.

Bulls say / Bears say

Patient Direct segment revenue increased 5.7% YoY to $673.9 million in Q1 2025, with operating margin growing 173 basis points to 8.92% and mid-teens EBITDA growth, showing effective strategy shift to higher-margin home-care services (Investing.com May 8, 2025 turn6search1).
Management reiterated its full-year 2025 guidance—expecting revenue of $10.85–$11.15 billion, adjusted EBITDA of $560–$590 million, and adjusted EPS of $1.60–$1.85—reflecting confidence in the company’s performance and sustained demand amid uncertain macro conditions (Investing.com May 8, 2025 turn6search1).
The Board approved a $100 million share buyback program on February 26, 2025, underscoring strong cash flow and management’s commitment to returning capital to shareholders, which could support the stock price and shareholder interests (SEC 10-Q Mar 31, 2025 turn9search1).
Products & Healthcare Services segment operating income dropped to $1.2 million in Q1 2025 from $11.5 million a year earlier, due to a $17 million decline in revenue and ongoing margin pressure in the core distribution business (SEC 10-Q turn3search5).
Owens & Minor mutually ended its $1.36 billion Rotech acquisition on June 5, 2025, paying an $80 million termination fee and reversing $1 billion of notes, highlighting regulatory and integration challenges that eliminate expected home-care growth synergies (Business Wire June 5 2025) turn2search3.
S&P Global Ratings changed OMI’s outlook to negative because leverage was at 4.4× in 2024 and is projected to exceed 5× in 2025, pointing to refinancing risk and the chance of ratings downgrades if the Products & Healthcare Services sale does not sufficiently lower debt (Reuters via Investing.com Mar 21, 2025 turn8search2).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Owens & Minor Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Owens & Minor Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OMI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs